- Reuters•3 days ago
Teva Pharmaceutical raised more than US$20bn across three currencies this week via an acquisition-driven bond that took advantage of pent-up demand for corporate paper in a yield-starved market. Investors had been making space for the well-telegraphed deal ever since Teva announced its US$40.5bn acquisition of Allergan Generics earlier in the year, while declining rates across the developed world and a lack of recent supply in the US and European markets added impetus to the transaction. In Europe, Teva issued bonds that priced up to 35bp inside its secondary curve - and those outstanding bonds, in turn, tightened by an incredible 40bp during the execution process.
- The Wall Street Journal•4 days ago
Amgen and Allergan on said a late-stage trial of their treatment being developed as a biosimilar to Roche’s breast cancer drug Herceptin met its primary endpoint.
|Bid||248.84 x 100|
|Ask||248.98 x 100|
|52wk Range||195.50 - 340.34|
|Day's Range||247.19 - 250.29|
|Avg Vol (3m)||3,574,328|
As of 9:58 AM EDT. NYSE Real Time Price. Market open.